Key statistics
On Friday, Editas Medicine Inc (8EM:FRA) closed at 1.44, 73.48% above the 52 week low of 0.8272 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.38 |
|---|---|
| High | 1.44 |
| Low | 1.38 |
| Bid | 1.48 |
| Offer | 1.49 |
| Previous close | 1.44 |
| Average volume | 1.84k |
|---|---|
| Shares outstanding | 97.62m |
| Free float | 97.35m |
| P/E (TTM) | -- |
| Market cap | 171.81m USD |
| EPS (TTM) | -2.38 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 13:34 GMT.
More ▼
Announcements
- Editas Medicine Announces Third Quarter 2025 Results and Business Updates
- Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
- Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
- Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
- Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
- Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Second Quarter 2025 Results and Business Updates
- Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
- Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
More ▼
